N4 Pharma
N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.
Latest Content
Product News
N4 Pharma Collaboration With SRI International Demonstrates Nuvec® Nanoparticle Successfully Targets Lung Cancer Cells
N4 Pharma and SRI show Nuvec® can precisely deliver RNA therapies to cancer cells, advancing targeted oncology treatments.
Product News
N4 Pharma Announces Collaboration With SRI To Target and Treat Cells in the Human Body That Have Been Previously Unreachable
N4 Pharma Plc, the company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, has entered into a research collaboration agreement with SRI.
Advertisement
